Niagen Bioscience (NAGE) Insider Ann Cohen Buys 31,746 Shares

Ann Cohen recently bought 31,746 shares of Niagen Bioscience, Inc. (NasdaqCM: NAGE) on June 24, 2026. The purchase was part of a series of insider buys on the same day, with the stock trading near $3.42.

Insider Buying and Selling at Niagen Bioscience, Inc.

On June 24, 2026, several insiders including Ann Cohen, Jaksch Frank Jr, Ng Wang Yu Gary, Patrick Kristin, Rubin Steven, and Shahbazi Hamed each bought 31,746 shares of Niagen Bioscience. These transactions were not part of a pre-planned trading program.

Other Institutional Activity in Niagen Bioscience

Institutional investors have also been active in Niagen Bioscience. BlackRock, Inc. trimmed its holdings by 204,090 shares, ending with 3,871,619 shares valued at about $17.1 million. SteelPeak Wealth, LLC opened a new position with 3,373,000 shares worth approximately $14.9 million. Arrowstreet Capital, Limited Partnership increased its stake by 761,685 shares, resulting in 2,378,437 shares valued at around $10.5 million. Vanguard Capital Management LLC also initiated a new position with 2,149,277 shares valued at approximately $9.5 million. Meanwhile, Tieton Capital Management, LLC and Qube Research & Technologies Ltd boosted their holdings by 384,062 and 652,804 shares, respectively.

Niagen Bioscience, Inc. Stock Up 14.4%

Shares of NasdaqCM:NAGE traded near $3.42 on Saturday. Niagen Bioscience, Inc. has a market capitalization of approximately $272.4 million and a P/E ratio of 16.3. The company's stock has a 52-week low of $3.29 and a high of $14.69. It has a 50-day moving average of $3.99 and a 200-day moving average of $5.83. Niagen's current and quick ratios are 4.61 and 3.48, respectively, with a debt-to-equity ratio of 3.13.

Analysts Set New Price Targets

Analysts have shown continued interest in Niagen Bioscience. On May 11, 2026, HC Wainwright & Co. maintained a 'buy' rating with an $11.00 price target. Canaccord Genuity, on May 5, 2026, also maintained a 'buy' rating with a $10.00 target. The consensus among analysts is a 'buy' rating with an average price target of $12.60 based on five opinions.

About Niagen Bioscience

Niagen Bioscience, Inc., headquartered in Los Angeles, California, is a bioscience company focused on developing products for healthy aging. It operates across several segments, including consumer products, ingredients, and pharmaceuticals. The company offers dietary supplements featuring its proprietary ingredients and commercializes nicotinamide riboside under the NIAGEN brand. Founded in 1999, Niagen Bioscience distributes its products through online platforms and various retail channels.

Bottom Line

Ann Cohen's purchase of Niagen Bioscience shares highlights ongoing insider interest in the company. The stock's recent trading activity and analyst ratings suggest continued attention from both insiders and institutions. Investors often watch these transactions for insights, though it's important to remember that insider buys and analyst ratings are part of a broader picture. Always consider the full context, including that 13F filings and insider reports are backward-looking and may not represent current positions.